Re: Cardiovascular Safety of β3-Adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2016年 / 196卷 / 05期
关键词：
D O I：
10.1016/j.juro.2016.08.038
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1507 / +
页数：2
相关论文
共 50 条
  • [31] β3-adrenoceptor agonists synergize with antimuscarinics
    Peter Sidaway
    Nature Reviews Urology, 2016, 13 : 496 - 496
  • [32] Re: Cardiovascular Safety of Vibegron, a New β3-Adrenoceptor Agonist, in Older Patients with Overactive Bladder: Post-Hoc Analysis of a Randomized, Placebo-Controlled, Double-Blind Comparative Phase 3 Study
    不详
    JOURNAL OF UROLOGY, 2022, 207 (02): : 441 - 441
  • [33] β3-Adrenoceptor (β3AR) agonists for the treatment of voiding dysfunction
    Michel, Martin C.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 36P - 36P
  • [34] Re: Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Editorial Comment - Re: Randomized Double-Blind, Active-Controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder Editorial Comment
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2013, 189 (06): : 2204 - 2205
  • [35] Association between polymorphism of β3-adrenoceptor gene and overactive bladder: a meta-analysis
    Qu, H. C.
    Zhang, W.
    Liu, Y. L.
    Wang, P.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (01): : 2495 - 2501
  • [36] Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder
    Tyagi, Pradeep
    Tyagi, Vikas
    IDRUGS, 2010, 13 (10) : 713 - 722
  • [37] Patient-reported outcomes with the 3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
    Khullar, Vik
    Amarenco, Gerard
    Angulo, Javier C.
    Blauwet, Mary Beth
    Nazir, Jameel
    Odeyemi, Isaac A.
    Hakimi, Zalmai
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 (08) : 987 - 994
  • [38] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Chapple, Christopher R.
    Nitti, Victor W.
    Khullar, Vik
    Wyndaele, Jean Jacques
    Herschorn, Sender
    van Kerrebroeck, Philip
    Blauwet, Mary Beth
    Siddiqui, Emad
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1565 - 1572
  • [39] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
    Christopher R. Chapple
    Victor W. Nitti
    Vik Khullar
    Jean Jacques Wyndaele
    Sender Herschorn
    Philip van Kerrebroeck
    Mary Beth Blauwet
    Emad Siddiqui
    World Journal of Urology, 2014, 32 : 1565 - 1572
  • [40] EFFICACY OF THE β3-ADRENOCEPTOR AGONIST MIRABEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) IN PATIENTS WITH INCONTINENCE: PROSPECTIVE POOLED ANALYSIS OF 3 RANDOMIZED PHASE 3 TRIALS
    Nitti, Victor
    Barkin, Jack
    Van Kerrebroeck, Philip
    Jeffrey, Frankel
    Mitcheson, David
    Blauwet, Mary Beth
    Siddiqui, Emad
    Martin, Nancy
    JOURNAL OF UROLOGY, 2013, 189 (04): : E561 - E561
12345